NCT00001520View on ClinicalTrials.gov

The Early Reversibility of Rocuronium After Different Doses of Neostigmine

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 1996

Study Completion Date

August 31, 2000

Conditions
Paralysis
Interventions
DRUG

neostigmine

Trial Locations (1)

20892

Warren G. Magnuson Clinical Center (CC), Bethesda

All Listed Sponsors
lead

National Institutes of Health Clinical Center (CC)

NIH

NCT00001520 - The Early Reversibility of Rocuronium After Different Doses of Neostigmine | Biotech Hunter | Biotech Hunter